Johns Hopkins study links mild dilatation of the pancreatic duct to a better risk of cancer

Pancreatic ductal adenocarcinoma is anticipated to be the second leading explanation for cancer death in america by 2030, in line with the National Institutes of Health (NIH). The International Cancer of the Pancreas Screening (CAPS) Consortium, the American Society for Gastrointestinal Endoscopy, and the National Comprehensive Cancer Network currently recommend surveillance of high-risk individuals, including those with multiple immediate blood relatives who’ve had pancreatic cancer and those that have been identified as having a genetic predisposition. In a brand new Johns Hopkins Medicine study funded partly by the NIH, researchers found that mild dilation or enlargement of the pancreatic duct is a cancer risk factor that needs to be monitored in high-risk people.

The study was published in November 2025.

We discover pancreatic duct dilatation as an early sign of pancreatic cancer in high-risk individuals, even within the absence of a visual mass. This finding may lead to higher possibilities of survival if cancers are detected early.”

Marcia Irene Canto, MD, MHS, Professor of Medicine and Oncology, Johns Hopkins University School of Medicine

In line with Canto, this investigation is an element of the CAPS study, an ongoing, long-term, prospective cohort study of high-risk individuals with a familial or genetic predisposition to developing pancreatic adenocarcinoma. The study was initiated in 1998. Johns Hopkins Kimmel Cancer is a pacesetter in pancreatic research and patient care.

On this study, experts from Johns Hopkins Medicine evaluated the outcomes of a CAPS cohort of 641 high-risk people. During routine surveillance with endoscopic ultrasound and MRI, researchers measured participants’ pancreatic ducts and located that patients with a duct diameter greater than 4 millimeters were more more likely to have high-grade dysplasia or cancer. Moreover, participants with enlarged pancreatic ducts had a better risk of developing early cancer.

Of the 641 participants examined, 97 showed enlargement without evidence of an obstructing mass lesion; Ten of them were diagnosed with neoplastic progression inside a mean of two years after the initial discovery of dilatation. The cumulative probability of pancreatic cancer with initial duct dilatation was 16% at five years and 26% at ten years. Participants were 2.6 times more more likely to receive a cancer diagnosis, particularly those that had greater than three pancreatic cysts during surveillance.

“By identifying this risk factor early, we were in a position to intervene more quickly,” says Canto. “The procedure would involve either surgery or far more common imaging. It was notable that even with one of the best imaging technology, a pancreatic cancer mass might not be visible, even when it causes structural changes within the gland. We now have the chance to do higher.”

Canto says this early warning sign of pancreatic duct dilatation could possibly be a precious finding that will be identified with other kinds of diagnostic imaging, akin to a CT scan performed for unrelated health problems akin to kidney stones stomach pain.

“The expansion is a warning signal [in high-risk patients]” says Canto. “Providers needs to be aware that that is something that should be addressed immediately.”

In line with Canto, the subsequent step in research is to make use of artificial intelligence to investigate imaging and clinical information to make more specific and accurate risk predictions.

This work was supported by NIH grants U01210170 and R01CA176828. Additional funding sources include Susan Wojcicki and Dennis Troper in addition to a Pancreatic Cancer Interception Translational Cancer Research Grant from the Stand As much as Cancer-Lustgarten Foundation (grant number: SU2CAACR-

DT25-17), administered by the American Association for Cancer Research. This work was also supported by the Pancreatic Cancer Motion Network, the Rolfe Pancreatic Cancer Foundation, the V Foundation, the Hooven Memorial Fund, the Victor Family Pancreatic Cancer Fund, and the Pancreatic Cancer Hope Foundation.

Additional researchers include Elizabeth Abou Diwan, MD, Helena Saba, MD, Amanda L. Blackford, Sc.M., Mohamad Dbouk, MD, Linda Chu, MD, Jin He, MD, Richard Burkhart, MD, Ralph H. Hruban, MD, and Michael Goggins, MD

Canto has received research grants from Pentax Medical Corporation and Merit Medical Corporation. She is a consultant for Castle Biosciences and Clear Note Health and receives royalties from UpToDate. Hruban has the potential to receive royalties from Thrive Early Detection for the GNAS invention in a relationship sponsored by Johns Hopkins University. All other authors provide no information.